Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.
The VIRI news archive on Stock Titan provides historical coverage of Virios Therapeutics, Inc., a development-stage biotechnology company that focused on antiviral combination therapies for conditions such as fibromyalgia and Long-COVID. Company press releases repeatedly describe Virios Therapeutics’ strategy of combining antiviral agents with celecoxib to suppress herpesvirus replication and address diseases associated with a viral-triggered abnormal immune response.
Readers can review news items detailing clinical and corporate milestones. These include updates on the IMC-2 Long-COVID program, such as the Bateman Horne Center’s randomized, double-blind, placebo-controlled Phase 2a study and earlier exploratory work reporting reductions in fatigue, orthostatic intolerance, pain and anxiety with the valacyclovir and celecoxib combination. News releases also discuss the development status of IMC-1, a fixed-dosage combination of famciclovir and celecoxib that has received FDA Fast Track designation for fibromyalgia.
The archive further documents financing activities, including public offerings intended to support planned Long-COVID studies, as well as patent developments like the publication of a global patent application covering IMC-2 for Alzheimer’s and COVID-19. A key set of news items covers the announced business Combination between Virios Therapeutics and Wex Pharmaceuticals, Inc., the adoption of the Dogwood Therapeutics, Inc. name, and the transition of trading from the VIRI ticker to DWTX on the Nasdaq Capital Market.
By browsing these historical news releases, investors and researchers can trace how Virios Therapeutics’ antiviral programs evolved and how they were integrated into the broader Dogwood Therapeutics pipeline. This context can be useful for understanding the scientific and corporate background behind the current Dogwood Therapeutics, Inc. disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Virios Therapeutics (Nasdaq: VIRI) has received initial feedback from the FDA regarding its Phase 3 program proposal for IMC-1, a combination treatment targeting fibromyalgia. The FDA considers the proposal acceptable, pending review of final toxicology program results. The proposed Phase 3 program includes two controlled clinical studies and a long-term safety trial. Final toxicology results will be submitted in May 2023, with further updates expected as the FDA review progresses. This program aims to address the significant unmet medical need in the fibromyalgia community, as no new treatments have been FDA-approved for this condition in over a decade.
Virios Therapeutics (Nasdaq: VIRI) reported its financial results for Q4 and full-year 2022. The company experienced a significant reduction in R&D expenses, totaling $1.3 million in Q4 2022, down from $2.9 million in Q4 2021. General and administrative expenses also fell to $0.8 million in Q4 2022 from $1.3 million in Q4 2021. The net loss for Q4 2022 stood at $2.0 million, or $0.11 per share, compared to a loss of $4.5 million, or $0.54 per share, a year earlier. For the full year 2022, the net loss was $12.2 million, down from $16.0 million in 2021. As of year-end, the company held $7.0 million in cash, with funding anticipated through mid-2024 for ongoing programs.
FAQ
What is the current stock price of Virios Therapeutics (VIRI)?
What is the market cap of Virios Therapeutics (VIRI)?
